FDCDDQ
FATE icon

Federation des caisses Desjardins du Quebec’s Fate Therapeutics FATE Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114 Hold
95
– – ﹤0.01% 2904
2025
Q4 		$93 Hold
95
– – ﹤0.01% 2819
2025
Q3 		$120 Hold
95
– – ﹤0.01% 2802
2025
Q2 		$106 Hold
95
– – ﹤0.01% 2661
2025
Q1 		$75 Hold
95
– – ﹤0.01% 2607
2024
Q4 		$157 Hold
95
– – ﹤0.01% 2463
2024
Q3 		$333 Hold
95
– – ﹤0.01% 2424
2024
Q2 		$312 Hold
95
– – ﹤0.01% 2296
2024
Q1 		$697 Hold
95
– – ﹤0.01% 2216
2023
Q4 		$355 Hold
95
– – ﹤0.01% 2223
2023
Q3 		$201 Hold
95
– – ﹤0.01% 2272
2023
Q2 		$452 Hold
95
– – ﹤0.01% 2203
2023
Q1 		$542 Hold
95
– – ﹤0.01% 2206
2022
Q4 		$959 Hold
95
– – ﹤0.01% 2286
2022
Q3 		$2.13K Hold
95
– – ﹤0.01% 2253
2022
Q2 		$2.35K Hold
95
– – ﹤0.01% 2285
2022
Q1 		$3.68K Buy
95
+32
+51% +$1.24K ﹤0.01% 2266
2021
Q4 		$3.69K Buy
+63
New +$3.57K ﹤0.01% 2270

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's FATE Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec held its Fate Therapeutics (FATE) position steady in Q1 2026 at 95 shares worth $114. The position accounts for ﹤0.01% of the portfolio, ranked #2904.

Federation des caisses Desjardins du Quebec first reported a position in FATE in Q4 2021 and has held it in 18 quarters since. The position peaked at $3.69K in Q4 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Federation des caisses Desjardins du Quebec held 95 shares of Fate Therapeutics worth $114 as of Q1 2026.
  • Federation des caisses Desjardins du Quebec left its Fate Therapeutics share count unchanged in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #2904 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in Fate Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Federation des caisses Desjardins du Quebec's Fate Therapeutics position peaked at $3.69K in Q4 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.